专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070077301A1 Venlafaxine osmotic device formulation 审中-公开
标题翻译：文拉法辛渗透装置制剂
公开(公告)号：US20070077301A1
公开(公告)日：2007-04-05
申请号：US11532186
申请日：2006-09-15
申请人： Glenn Meyer , Marcelo Ricci , Guido Bigatti
发明人： Glenn Meyer , Marcelo Ricci , Guido Bigatti
IPC分类号： A61K9/24 , A61K31/137
CPC分类号： A61K9/0004 , A61K9/2018 , A61K31/137
摘要： The present invention provides an osmotic device containing controlled release venlafaxine in the core, wherein the osmotic device exhibits a reduced food effect as compared to a reference controlled release capsule formulation. Some embodiments include venlafaxine in controlled release form in combination with an anti-Alzheimer's or an anti-Parkinson's drug in a rapid release external coat. Memantine is used as an anti-Alzheimer's drug or an anti-Parkinson's drug. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray-coated rather than compression-coated onto the device. The device is useful for the treatment of depression in Alzheimer's and/or Parkinson's patients. The device and method can also be used to treat or ameliorate other symptoms associated with Alzheimer's disease, Parkinson's disease or any other neurological disorder. Other dosage forms that provide a controlled, sustained or extended release of venlafaxine in combination with a rapid or immediate release of memantine are useful in the invention.
摘要翻译：本发明提供一种渗透装置，其含有核心中的文拉法苦心，其中渗透装置与参考控释胶囊制剂相比表现出降低的食物效果。一些实施方案包括与快速释放外涂层中的抗阿尔茨海默氏病或抗帕金森氏病药物组合的控释药物的文拉法辛。美金刚被用作抗阿尔茨海默病药物或抗帕金森氏药物。本发明的具体实施方案提供具有预定释放特征的渗透装置。渗透装置的一个实施例包括已经被喷涂而不是被压缩涂覆到该装置上的外部涂层。该装置可用于治疗阿尔茨海默病和/或帕金森氏症患者的抑郁症。该装置和方法还可用于治疗或改善与阿尔茨海默病，帕金森病或任何其他神经障碍相关的其它症状。提供文拉法辛与美金刚的快速或立即释放相结合的受控，持续或延长释放的其它剂型在本发明中是有用的。

2. 发明申请

US20060159763A1 Osmotic device containing amantadine and an osmotic salt 有权
标题翻译：渗透装置含有金刚烷胺和渗透盐
公开(公告)号：US20060159763A1
公开(公告)日：2006-07-20
申请号：US11287882
申请日：2005-11-28
申请人： Glenn Meyer , Ethel Feleder , Marcelo Ricci , Marcelo Coppari , Marcelo Befumo , Joaquina Faour , Juan Vergez
发明人： Glenn Meyer , Ethel Feleder , Marcelo Ricci , Marcelo Coppari , Marcelo Befumo , Joaquina Faour , Juan Vergez
IPC分类号： A61K31/13 , A61K9/24
CPC分类号： A61K9/0004
摘要： The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is modified from a first order release profile to a zero order, pseudo-zero order or sigmoidal release profile by increasing the amount of the osmotic salt in the core of the device. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt.
摘要翻译：本发明的渗透装置含有包含金刚烷胺和渗透盐的盐的单一核心，其中两种盐具有共同的离子。金刚烷胺的释放速率通过增加器件芯体中的渗透盐的量从一级释放曲线修改为零级，伪零级或S形释放曲线。渗透装置包括具有受控孔隙度的半透膜，其可以根据需要进行调整，以与渗透盐配合以提供预定的药物释放曲线。渗透盐不需要涂覆，并且与金刚烷胺盐混合。

3. 发明申请

US20060063810A1 Combination treatment for impaired motor function in parkinson's disease 审中-公开
标题翻译：帕金森病运动功能受损的组合治疗
公开(公告)号：US20060063810A1
公开(公告)日：2006-03-23
申请号：US11215797
申请日：2005-08-30
申请人： Juan Vergez , Alan Lanier , Ethel Feleder , Glenn Meyer , Marcelo Ricci , Joaquina Faour
发明人： Juan Vergez , Alan Lanier , Ethel Feleder , Glenn Meyer , Marcelo Ricci , Joaquina Faour
IPC分类号： A61K31/452 , A61K31/343 , A61K31/137
CPC分类号： A61K45/06 , A61K31/00 , A61K31/137 , A61K31/343 , A61K31/452 , A61K2300/00
摘要： The invention provides a method, and dosage form therefor, of treating impaired motor function associated with Parkinson's disease, anti-Parkinson's drug treatment, e.g. L-Dopa therapy, and/or dementia associated with Parkinson's disease. The invention includes the combined administration of an NMDA receptor antagonist and an antidepressant, e.g., the combination of amantadine and citalopram or venlafaxine, or an NMDA receptor antagonist and an anxiolytic agent, e.g., amantadine and buspirone or trazodone, for the amelioration of undesired tremors, akinesia, dyskinesia, or bradykinesia associated with one or more different disorders or diseases. The drugs can be included in a single dosage form. One embodiment includes a combination dosage form containing each drug in controlled release forms. Another embodiment includes a combination dosage form providing a controlled release of an NMDA receptor antagonist and a rapid release of a neuroactive agent after administration to a subject.
摘要翻译：本发明提供了治疗与帕金森病相关的运动功能障碍，抗帕金森氏病药物治疗的方法及其剂型。左旋多巴治疗和/或与帕金森病有关的痴呆症。本发明包括联合施用NMDA受体拮抗剂和抗抑郁药，例如金刚烷胺和西酞普兰或文拉法辛，或NMDA受体拮抗剂和抗焦虑剂（例如金刚烷胺和丁螺环酮或曲唑酮）的组合，用于改善不期望的颤抖，运动障碍，运动障碍或与一种或多种不同疾病或疾病相关的运动迟缓。药物可以包含在单一剂型中。一个实施方案包括含有受控释放形式的每种药物的组合剂型。另一个实施方案包括提供NMDA受体拮抗剂的受控释放的组合剂型和在施用于受试者之后神经活性剂的快速释放。

4. 发明申请

US20070275060A1 Extended release solid pharmaceutical composition containing carbidopa and levodopa 审中-公开
标题翻译：含有卡比多巴和左旋多巴的延长释放固体药物组合物
公开(公告)号：US20070275060A1
公开(公告)日：2007-11-29
申请号：US11498307
申请日：2006-08-02
申请人： Marcelo Befumo , Marcelo Ricci , Ethel Feleder , Glenn Meyer , Joaquina Faour , Juan Vergez
发明人： Marcelo Befumo , Marcelo Ricci , Ethel Feleder , Glenn Meyer , Joaquina Faour , Juan Vergez
IPC分类号： A61K31/137 , A61P25/16 , A61K9/24
CPC分类号： A61K9/2009 , A61K9/2054 , A61K9/209 , A61K9/2866 , A61K31/137 , A61K31/198 , A61K45/06
摘要： The invention provides a compressed tablet that provides a extended release tablet containing a extended release form of carbidopa and a extended release form of levodopa. The tablet optionally further comprises an immediate or rapid release composition of carbidopa and/or levodopa. The extended release composition in the tablet excludes a release rate-controlling polymer, and a release rate-controlling coating; however, the release of the carbidopa and/or levodopa is independently optionally delayed for a lag time. The invention also provides a tablet having a extended release form of levodopa and a rapid or immediate release form of carbidopa. A tablet can contain levodopa present in extended release form and rapid or immediate release form, and carbidopa present in extended release form and rapid or immediate release form. The tablet is used to treat Parkinson's disease and other movement related disorders, diseases or syndromes.
摘要翻译：本发明提供一种压缩片剂，其提供含有延迟释放形式的卡比多巴和延长释放形式的左旋多巴的延长释放片剂。片剂任选地还包含卡比多巴和/或左旋多巴的立即或快速释放组合物。片剂中的延长释放组合物不包括释放速率控制聚合物和释放速率控制涂层; 然而，卡比多巴和/或左旋多巴的释放独立地任选延迟滞后时间。本发明还提供具有延长释放形式的左旋多巴的片剂和卡比多巴的快速或立即释放形式。片剂可以含有以延长释放形式存在的左旋多巴和快速或立即释放形式，以及以延长释放形式存在的卡比多巴和快速或即时释放形式。该片用于治疗帕金森病和其他与运动相关的疾病，疾病或综合征。

5. 发明申请

US20050163851A1 Osmotic device containing a venlafaxine salt and a salt having an ion in common 有权
标题翻译：渗透装置含有文拉法辛盐和具有共同离子的盐
公开(公告)号：US20050163851A1
公开(公告)日：2005-07-28
申请号：US11010829
申请日：2004-12-13
申请人： Ethel Feleder , Glenn Meyer , Marcelo Ricci , Joaquina Faour , Ana Pastini , Marcelo Befumo
发明人： Ethel Feleder , Glenn Meyer , Marcelo Ricci , Joaquina Faour , Ana Pastini , Marcelo Befumo
IPC分类号： A61K9/00 , A61K9/24 , A61K31/13 , A61K31/137 , A61K31/277
CPC分类号： A61K9/0004 , A61K31/13 , A61K31/137 , A61K31/277
摘要： The osmotic devices of the present invention include a single core comprising a salt of a drug and an osmotic salt, wherein the drug salt and the osmotic salt have a common ion. The release rate of the active drug is reduced, and the release profile of the active drug is modified, from a first order release profile to a zero order, pseudo-zero order, or sigmoidal release profile, by increasing the amount of the sodium chloride in the core of the device. In one embodiment the sodium chloride is used to modify a controlled release profile to a delayed and controlled release profile.
摘要翻译：本发明的渗透装置包括包含药物和渗透盐的盐的单核心，其中药物盐和渗透盐具有共同的离子。活性药物的释放速率降低，并且通过增加氯化钠的量，将活性药物的释放曲线从一级释放曲线修改为零级，伪零级或S形释放曲线在设备的核心。在一个实施方案中，氯化钠用于将受控释放曲线修饰为延迟和控制释放曲线。

6. 发明申请

US20050259270A1 Fiberoptic fabry-perot optical processor 审中-公开
标题翻译： Fiberoptic fabry-perot光学处理器
公开(公告)号：US20050259270A1
公开(公告)日：2005-11-24
申请号：US11134548
申请日：2005-05-20
申请人： Michael Pocha , Charles McConaghy , Billy Wood , Glenn Meyer
发明人： Michael Pocha , Charles McConaghy , Billy Wood , Glenn Meyer
IPC分类号： G01B9/02 , G01D5/353 , G01J3/26 , G01J9/02 , G01K11/32 , G01N21/25 , G02B5/04 , G02B27/10 , G06E1/00
CPC分类号： G01B9/02051 , G01B9/02027 , G01B9/02081 , G01B2290/25 , G01B2290/45 , G01D5/35303 , G01J1/0209 , G01J1/0407 , G01J1/0477 , G01J3/0205 , G01J3/0259 , G01J3/26 , G01J2009/023 , G01K11/3213 , G02B5/04 , G02B27/1006 , G02B27/144 , G02B27/145
摘要： An optical signal processor having a monolithic prism supporting one or more channels, and constructed from a first glass block joined to a second glass block at a beam splitter interface. The monolithic prism has thin film beam splitters and filters (such as I and Q filters) either deposited directly on the prism or attached to it. The beam splitter interface, and the thin film beam splitters and filters are arranged relative to each other so that a portion of the return-ranging collimated encoded beam from an external optical sensor is reflected to all the filters. And detectors are connected over the filters to detect particular components of the collimated encoded beam which are passed through the respective filters.
摘要翻译：光学信号处理器具有支撑一个或多个通道的单片棱镜，并且由在分束器接口处连接到第二玻璃块的第一玻璃块构成。单片棱镜具有薄膜分束器和滤波器（例如I和Q滤波器），其直接沉积在棱镜上或附着于其上。分束器接口和薄膜分束器和滤波器相对于彼此布置，使得来自外部光学传感器的返回测距准直编码光束的一部分被反射到所有滤光器。并且检测器通过滤波器连接以检测通过相应滤波器的准直编码波束的特定分量。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式